For research use only. Not for therapeutic Use.
Barzolvolimab (CDX 0159) is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria[1].
Barzolvolimab binds the extracellular domain of KIT with high specificity and sub-nanomolar affinity, and allosterically inhibits activation by stem cell factor (SCF)[1].
| Catalog Number | I042162 |
| CAS Number | 2438203-51-9 |
| Purity | ≥95% |
| Reference | [1]. Terhorst-Molawi D, et, al. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 2022 Nov 16. |
